222 related articles for article (PubMed ID: 37489549)
21. Minimal residual disease-guided treatment deintensification for children with acute lymphoblastic leukemia: results from the Malaysia-Singapore acute lymphoblastic leukemia 2003 study.
Yeoh AE; Ariffin H; Chai EL; Kwok CS; Chan YH; Ponnudurai K; Campana D; Tan PL; Chan MY; Kham SK; Chong LA; Tan AM; Lin HP; Quah TC
J Clin Oncol; 2012 Jul; 30(19):2384-92. PubMed ID: 22614971
[TBL] [Abstract][Full Text] [Related]
22. Significance of the complete clearance of peripheral blasts after 7 days of prednisolone treatment in children with acute lymphoblastic leukemia: the Tokyo Children's Cancer Study Group Study L99-15.
Manabe A; Ohara A; Hasegawa D; Koh K; Saito T; Kiyokawa N; Kikuchi A; Takahashi H; Ikuta K; Hayashi Y; Hanada R; Tsuchida M;
Haematologica; 2008 Aug; 93(8):1155-60. PubMed ID: 18519521
[TBL] [Abstract][Full Text] [Related]
23. Treatment outcome and prognostic factors for infants with acute lymphoblastic leukemia treated on two consecutive trials of the Children's Cancer Group.
Reaman GH; Sposto R; Sensel MG; Lange BJ; Feusner JH; Heerema NA; Leonard M; Holmes EJ; Sather HN; Pendergrass TW; Johnstone HS; O'Brien RT; Steinherz PG; Zeltzer PM; Gaynon PS; Trigg ME; Uckun FM
J Clin Oncol; 1999 Feb; 17(2):445-55. PubMed ID: 10080584
[TBL] [Abstract][Full Text] [Related]
24. Reinduction platform for children with first marrow relapse of acute lymphoblastic Leukemia: A Children's Oncology Group Study[corrected].
Raetz EA; Borowitz MJ; Devidas M; Linda SB; Hunger SP; Winick NJ; Camitta BM; Gaynon PS; Carroll WL
J Clin Oncol; 2008 Aug; 26(24):3971-8. PubMed ID: 18711187
[TBL] [Abstract][Full Text] [Related]
25. Early responses to chemotherapy of normal and malignant hematologic cells are prognostic in children with acute lymphoblastic leukemia.
Laughton SJ; Ashton LJ; Kwan E; Norris MD; Haber M; Marshall GM
J Clin Oncol; 2005 Apr; 23(10):2264-71. PubMed ID: 15800317
[TBL] [Abstract][Full Text] [Related]
26. The evolution of acute lymphoblastic leukemia research and therapy at MD Anderson over four decades.
Jabbour E; Short NJ; Jain N; Haddad FG; Welch MA; Ravandi F; Kantarjian H
J Hematol Oncol; 2023 Mar; 16(1):22. PubMed ID: 36927623
[TBL] [Abstract][Full Text] [Related]
27. Survival outcome following isolated central nervous system relapse treated with additional chemotherapy and craniospinal irradiation in childhood acute lymphoblastic leukemia.
Kumar P; Kun LE; Hustu HO; Mulhern RK; Hancock ML; Coffey D; Rivera GK
Int J Radiat Oncol Biol Phys; 1995 Feb; 31(3):477-83. PubMed ID: 7852109
[TBL] [Abstract][Full Text] [Related]
28. Comparative outcomes of Thai children with acute lymphoblastic leukemia treated with two consecutive protocols: 11-year experience.
Surapolchai P; Pakakasama S; Sirachainan N; Anurathapan U; Songdej D; Chuansumrit A; Hongeng S
Leuk Lymphoma; 2012 May; 53(5):891-900. PubMed ID: 21988642
[TBL] [Abstract][Full Text] [Related]
29. Minimal residual disease values discriminate between low and high relapse risk in children with B-cell precursor acute lymphoblastic leukemia and an intrachromosomal amplification of chromosome 21: the Austrian and German acute lymphoblastic leukemia Berlin-Frankfurt-Munster (ALL-BFM) trials.
Attarbaschi A; Mann G; Panzer-Grümayer R; Röttgers S; Steiner M; König M; Csinady E; Dworzak MN; Seidel M; Janousek D; Möricke A; Reichelt C; Harbott J; Schrappe M; Gadner H; Haas OA
J Clin Oncol; 2008 Jun; 26(18):3046-50. PubMed ID: 18565891
[TBL] [Abstract][Full Text] [Related]
30. Neurocognitive and neuroradiologic central nervous system late effects in children treated on Pediatric Oncology Group (POG) P9605 (standard risk) and P9201 (lesser risk) acute lymphoblastic leukemia protocols (ACCL0131): a methotrexate consequence? A report from the Children's Oncology Group.
Duffner PK; Armstrong FD; Chen L; Helton KJ; Brecher ML; Bell B; Chauvenet AR
J Pediatr Hematol Oncol; 2014 Jan; 36(1):8-15. PubMed ID: 24345882
[TBL] [Abstract][Full Text] [Related]
31. Treatment of childhood acute lymphoblastic leukemia after the first relapse: curative strategies.
Uderzo C; Dini G; Locatelli F; Miniero R; Tamaro P
Haematologica; 2000 Nov; 85(11 Suppl):47-53. PubMed ID: 11268324
[TBL] [Abstract][Full Text] [Related]
32. Children's Cancer Group trials in childhood acute lymphoblastic leukemia: 1983-1995.
Gaynon PS; Trigg ME; Heerema NA; Sensel MG; Sather HN; Hammond GD; Bleyer WA
Leukemia; 2000 Dec; 14(12):2223-33. PubMed ID: 11187913
[TBL] [Abstract][Full Text] [Related]
33. A 50-year journey to cure childhood acute lymphoblastic leukemia.
Pui CH; Evans WE
Semin Hematol; 2013 Jul; 50(3):185-96. PubMed ID: 23953334
[TBL] [Abstract][Full Text] [Related]
34. High CD45 surface expression determines relapse risk in children with precursor B-cell and T-cell acute lymphoblastic leukemia treated according to the ALL-BFM 2000 protocol.
Cario G; Rhein P; Mitlöhner R; Zimmermann M; Bandapalli OR; Romey R; Moericke A; Ludwig WD; Ratei R; Muckenthaler MU; Kulozik AE; Schrappe M; Stanulla M; Karawajew L
Haematologica; 2014 Jan; 99(1):103-10. PubMed ID: 23911702
[TBL] [Abstract][Full Text] [Related]
35. Dasatinib Plus Intensive Chemotherapy in Children, Adolescents, and Young Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Results of Children's Oncology Group Trial AALL0622.
Slayton WB; Schultz KR; Kairalla JA; Devidas M; Mi X; Pulsipher MA; Chang BH; Mullighan C; Iacobucci I; Silverman LB; Borowitz MJ; Carroll AJ; Heerema NA; Gastier-Foster JM; Wood BL; Mizrahy SL; Merchant T; Brown VI; Sieger L; Siegel MJ; Raetz EA; Winick NJ; Loh ML; Carroll WL; Hunger SP
J Clin Oncol; 2018 Aug; 36(22):2306-2314. PubMed ID: 29812996
[TBL] [Abstract][Full Text] [Related]
36. The influence of maximum supportive care on dose compliance and survival. Single-center analysis of childhood acute lymphoblastic leukemia and non-Hodgkin's-lymphoma treated within 1984-1993.
Urban C; Benesch M; Lackner H; Schwinger W; Kerbl R; Gadner H
Klin Padiatr; 1997; 209(4):235-42. PubMed ID: 9293456
[TBL] [Abstract][Full Text] [Related]
37. Improving infectious adverse event reporting for children and adolescents enrolled in clinical trials for acute lymphoblastic leukemia: A report from the Children's Oncology Group.
Elgarten CW; Thompson JC; Angiolillo A; Chen Z; Conway S; Devidas M; Gupta S; Kairalla JA; McNeer JL; O'Brien MM; Rabin KR; Rau RE; Rheingold SR; Wang C; Wood C; Raetz EA; Loh ML; Alexander S; Miller TP
Pediatr Blood Cancer; 2022 Nov; 69(11):e29937. PubMed ID: 36083863
[TBL] [Abstract][Full Text] [Related]
38. [In vitro drug resistance as independent prognostic factor in the study COALL-O5-92 Treatment of childhood acute lymphoblastic leukemia; two-tiered classification of treatments based on accepted risk criteria and drug sensitivity profiles in study COALL-06-97].
Janka-Schaub GE; Harms DO; den Boer ML; Veerman AJ; Pieters R
Klin Padiatr; 1999; 211(4):233-8. PubMed ID: 10472556
[TBL] [Abstract][Full Text] [Related]
39. The genomic landscape of pediatric acute lymphoblastic leukemia and precision medicine opportunities.
Tran TH; Hunger SP
Semin Cancer Biol; 2022 Sep; 84():144-152. PubMed ID: 33197607
[TBL] [Abstract][Full Text] [Related]
40. Intrathecal triple therapy decreases central nervous system relapse but fails to improve event-free survival when compared with intrathecal methotrexate: results of the Children's Cancer Group (CCG) 1952 study for standard-risk acute lymphoblastic leukemia, reported by the Children's Oncology Group.
Matloub Y; Lindemulder S; Gaynon PS; Sather H; La M; Broxson E; Yanofsky R; Hutchinson R; Heerema NA; Nachman J; Blake M; Wells LM; Sorrell AD; Masterson M; Kelleher JF; Stork LC;
Blood; 2006 Aug; 108(4):1165-73. PubMed ID: 16609069
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
